Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.53% is 83% above its 5-year average of 0.29%, near the high end of its 5-year range (0.00%–0.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.51% above its 12-month average of 0.36%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.53%.
DEBT TO ASSETS RATIO
0.53%
DEBT TO ASSETS RATIO AVG TTM
0.36%
DEBT TO ASSETS RATIO AVG 3Y
0.30%
DEBT TO ASSETS RATIO AVG 5Y
0.29%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+46.51%
CURRENT VS 3Y AVG
+78.03%
CURRENT VS 5Y AVG
+83.43%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 526 covered companies
CURRENT VS SECTOR MEDIAN
+408.10%
vs the sector median at left
Climb Bio, Inc.
Market Cap
$620.73M
Debt to Assets Ratio
0.53%
TTM Avg
0.36%
3Y Avg
0.30%
5Y Avg
0.29%
Market Cap
$639.87M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$641.49M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$645.65M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$666.00M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$596.64M
Debt to Assets Ratio
1.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$593.84M
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$575.41M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $620.73M | 0.53% | 0.36% | 0.30% | 0.29% |
| Fulgent Genetics, Inc. (FLGT)vs › | $639.87M | 0.01% | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $641.49M | 0.05% | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $645.65M | 0.00% | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.00M | 0.08% | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $596.64M | 1.39% | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $593.84M | 0.18% | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $681.19M | 0.10% | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $575.41M | 0.00% | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.14M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.5%
Debt/Equity
0.01
Current Ratio
31.45
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.53% |
| 2026-03-31 | 0.31% |
| 2025-12-31 | 0.32% |
| 2025-09-30 | 0.32% |
| 2025-06-30 | 0.33% |
| 2025-03-31 | 0.24% |
| 2024-12-31 | 0.24% |
| 2024-09-30 | 0.03% |
| 2024-06-30 | 0.04% |
| 2024-03-31 | 0.21% |
| 2023-12-31 | 0.32% |
| 2023-09-30 | 0.41% |
| 2023-06-30 | 0.50% |
| 2023-03-31 | 0.56% |
| 2022-12-31 | 0.36% |
| 2022-09-30 | 0.41% |
| 2022-06-30 | 0.46% |
| 2022-03-31 | 0.52% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
